The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FY | Combinations of monoclonal antibodies and antibody drug conjugates |
| Code | Title | |
|---|---|---|
| L01FY01 | ||
| L01FY02 | ||
| L01FY03 |
| Active Ingredient | Description | |
|---|---|---|
| Pertuzumab and Trastuzumab |
Pertuzumab and trastuzumab are recombinant humanised IgG1 monoclonal antibodies which target the human epidermal growth factor receptor 2 (HER2). Both substances bind to distinct HER2 subdomains without competing and have complementary mechanisms for disrupting HER2 signalling. Additionally, both substances mediate antibody-dependent cell-mediated cytotoxicity (ADCC). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| OPDUALAG Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PHESGO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
